{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003965","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.423304+00:00","generated_at":"2026-06-07T02:26:07.996529+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum announces preliminary 2023 net product sales of $178-180M; LIVMARLI sales up 89% YoY","bullets":["Preliminary 2023 total revenue $186-188M; net product sales $178-180M.","LIVMARLI net product sales $141-143M, ~89% YoY growth.","Q4 2023 net product sales $69-71M (LIVMARLI $41-43M; CHOLBAM & CHENODAL ~$28M).","FDA PDUFA for LIVMARLI in PFIC on March 13, 2024; NDA submission for CHENODAL in CTX in H1 2024.","Appointed Eric Bjerkholt as CFO; company fully financed with strong balance sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003965","json":"https://secwatch.observer/filing/0001193125-24-003965.json","markdown":"https://secwatch.observer/filing/0001193125-24-003965.md","text":"https://secwatch.observer/filing/0001193125-24-003965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/0001193125-24-003965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/d754126d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:26:07.996529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4f8cdbb6e16e3835b800e01cc27f2e36eada8ca","claim":"Mirum Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $186-188 million.","evidence_excerpt":"Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/0001193125-24-003965-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$186-188 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}